Nationwide Access to Ultrafiltration Therapy Possible with Nuwellis and Premier, Inc. Collaboration
June 01 2021 - 7:00AM
Nuwellis, Inc. (Nasdaq: NUWE), formerly CHF Solutions, Inc., has
been awarded a three-year national contract with Premier, Inc.,
effective today. The new Aquapheresis category agreement allows
Premier members, at their discretion, to take advantage of special
pricing and terms pre-negotiated by Premier for Aquadex SmartFlow®,
the gentle fluid management technology developed by Nuwellis.
Aquadex® is the first and only therapy currently available in
this newly-established Aquapheresis product category. The
collaboration provides Nuwellis with the opportunity to expand into
many of the thousands of hospitals with which Premier holds
relationships.
“Premier is a trusted healthcare leader, and working with them
to expand access to ultrafiltration with Aquadex is a significant
milestone for the Company and the customers we serve,” said Nestor
Jaramillo, Jr., President and CEO of Nuwellis. “The immense value
of this collaboration will be felt by hospitals dedicated to
offering its patients with the most innovative technology. We’re
ultimately grateful for Premier’s dedication to deliver
transformative solutions that power real results.”
Nuwellis is dedicated to transforming the lives of patients
suffering from fluid overload – a condition associated with
multiple disease states that can cause a significant burden on
vital organs if left untreated. The Company prioritizes
collaboration and innovation to provide unsurpassed care to
pediatric, critical care and heart failure patients. Aquadex is
built to gently remove excess fluid with customizable rates to
improve patient outcomes.
Premier, Inc. is a leading healthcare improvement company,
uniting an alliance of more than 4,100 U.S. hospitals and health
systems and approximately 200,000 other providers and organizations
to transform healthcare. With integrated data and analytics,
collaboratives, supply chain solutions, and consulting and other
services, Premier enables better care and outcomes at a lower
cost.
The agreement was included in the expedited approval program
instituted by Premier to quickly offer COVID-19 innovations to
patients.
About NuwellisNuwellis, Inc.
(Nasdaq:NUWE), formally CHF Solutions, Inc., is a medical device
company dedicated to transforming the lives of patients suffering
from fluid overload through science, collaboration, and innovation.
The Company is focused on developing, manufacturing and
commercializing the Aquadex SmartFlow® System for ultrafiltration
therapy. Nuwellis is headquartered in Minneapolis, Minn., with a
wholly-owned subsidiary in Ireland. The Company has been listed on
the Nasdaq Capital Market since February 2012, previously branded
as CHF Solutions (Nasdaq:CHFS).
About the Aquadex SmartFlow
SystemThe Aquadex SmartFlow® System delivers clinically
proven therapy using a simple, flexible and smart method of
removing excess fluid from patients suffering from hypervolemia
(fluid overload). The Aquadex SmartFlow System is indicated for
temporary (up to 8 hours) or extended (longer than 8 hours in
patients who require hospitalization) use in adult and pediatric
patients weighing 20 kg or more whose fluid overload is
unresponsive to medical management, including diuretics. All
treatments must be administered by a health care provider, within
an outpatient or inpatient clinical setting, under physician
prescription, both having received training in extracorporeal
therapies.
Forward-Looking
StatementsCertain statements in this release may be
considered forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the new market opportunities and
anticipated growth in 2021 and beyond. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risks associated with our ability to execute on
our commercialization strategy, the impact of the COVID-19
pandemic, the possibility that we may be unable to raise sufficient
funds necessary for our anticipated operations, our post-market
clinical data collection activities, benefits of our products to
patients, our expectations with respect to product development and
commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and other risks and uncertainties described in our filings with
the SEC. Forward-looking statements speak only as of the date
when made. Nuwellis does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
CONTACTS
INVESTORS:
Nestor Jaramillo
President, Chief Executive Officer and Chief Financial Officer, Nuwellis, Inc.
ir@nuwellis.com
Matt Basco, CFA
Gilmartin Group LLC
Matt.basco@gilmartinir.com
MEDIA:
Jessica Stebing
Health+Commerce
jstebing@healthandcommerce.com
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jul 2023 to Jul 2024